Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Barr ciprofloxacin marketing continues

Executive Summary

Barr will continue to market authorized generic of Bayer's antibiotic Cipro (ciprofloxacin) during the product's expected pediatric exclusivity, which runs for six months beginning Dec. 9, under an amended agreement. Barr had a similar deal on AstraZeneca's breast cancer drug Nolvadex (tamoxifen) but was forced to drop its authorized generic during the pediatric exclusivity period (1"The Pink Sheet" Feb. 3, 2003, p. 13)...

You may also be interested in...

Bayer Cipro gets pediatric exclusivity

Bayer Cipro market exclusivity extended until June 9 after FDA grants six-month pediatric extension Dec. 18. Pediatric approval is based on 689-patient Cipro comparative trial; five-year, 1,029-patient observational study; and pharmacokinetic analysis. Although Bayer's patent expired Dec. 9, the product was protected by a 90-day review grace period following the Sept. 24 submission of the exclusivity application. Barr will continue to market its "authorized" ciprofloxacin generic through the pediatric exclusivity period (1"The Pink Sheet" Sept. 29, 2003, In Brief)...

AstraZeneca Self-Markets Nolvadex Generic; Zoladex Settlement Near

AstraZeneca is marketing its own generic version of Nolvadex (tamoxifen) to protect the company from claims that it is exploiting cancer patients in the final months of exclusivity for the drug

Podcast: The Week In European Consumer Health Industry News, 8 March 2021

HBW editors Tom Gallen and David Ridley discuss the big issues in the European consumer health market from the past week. In this edition, they delve into probiotics, digital health and Bayer’s recent turnaround.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts